EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ezh2 Inhibits the Differentiation of Short‐Lived Effector CD8 + T Cells and Promotes T Cell‐Dependent Antitumor Immunity

Kenji Takagi, Junpei Suzuki, Yuko Matsuoka, Makoto Kuwahara, Taro Oshikiri, Masakatsu Yamashita iD

Cancer Science · 2026

DOI: 10.1111/cas.70439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Kenji Takagi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery and Surgical Oncology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, CD8-Positive T-Lymphocytes, Cell Differentiation. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Naito Foundation, Takeda Medical Research Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Appropriate regulation of the differentiation balance between effector CD8 + T cells and memory CD8 + T cells is crucial for an appropriate immune response. We previously reported that the tumor suppressor menin suppresses the differentiation of CD8 + T cells into short‐lived effector T cells (SLECs) and positively regulates memory CD8 + T cell differentiation. In this study, we identified Ezh2, a histone H3K27 methyltransferase, as a factor responsible for regulating SLECs differentiation, located downstream of menin. In antigen‐stimulated CD8 + T cells, the Ezh2 expression gradually decreased with proliferation, reaching the lowest levels in terminally differentiated CD8 + T cells. The decrease in the expression of Ezh2 was accelerated by menin deficiency. Reduced histone H3K27 acetylation at the Ezh2 locus was observed in Menin ‐deficient CD8 + T cells, indicating that menin is required for maintaining the expression of Ezh2. In vitro studies have demonstrated that Ezh2 ‐deficient activated CD8 + T cells exhibit enhanced differentiation into SLECs, along with increased effector functions. In contrast, Ezh2‐deficient effector CD8 + T cells showed a marked increase in apoptosis upon IL‐2 removal. In studies using mouse tumor models, T cell‐specific Ezh2 knockout mice exhibited increased tumor growth and reduced survival relative to wild‐type mice, with a significant decrease in the number of tumor‐infiltrating CD8 + T cells. RNA sequencing revealed that Ezh2 ‐deficient effector CD8 + T cells exhibit the increased expression of terminal differentiation‐related molecules and apoptosis‐related genes. These results demonstrate that Ezh2 functions downstream of menin and is essential for the proper regulation of T cell‐dependent antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinCD8-Positive T-LymphocytesCell DifferentiationAnimalsMiceMice, KnockoutProto-Oncogene ProteinsHistonesMice, Inbred C57BLApoptosisLymphocyte ActivationHumans

Stichwörter der Autor:innen

Ezh2CD8+ T cellantitumor immunityhistone H3K27short‐lived effector cells

Substanzen

Enhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseProto-Oncogene ProteinsHistonesMen1 protein, mouse

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery and Surgical Oncology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
  • Department of Immunology, Ehime University, Graduate School of Medicine, Toon, Ehime, Japan.
  • Translational Research Center, Ehime University Hospital, Ehime University, Toon, Ehime, Japan.
  • Department of Infections and Host Defenses, Ehime University, Graduate School of Medicine, Toon, Ehime, Japan.

ORCID-Profile: Masakatsu Yamashita

Förderung

  • Naito Foundation
  • Takeda Medical Research Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Takagi, K., Suzuki, J., Matsuoka, Y., Kuwahara, M., Oshikiri, T., & Yamashita, M. (2026). Ezh2 Inhibits the Differentiation of Short‐Lived Effector CD8 + T Cells and Promotes T Cell‐Dependent Antitumor Immunity. Cancer Science. https://doi.org/10.1111/cas.70439

Vancouver

Takagi K, Suzuki J, Matsuoka Y, Kuwahara M, Oshikiri T, Yamashita M. Ezh2 Inhibits the Differentiation of Short‐Lived Effector CD8 + T Cells and Promotes T Cell‐Dependent Antitumor Immunity. Cancer Science. 2026. doi:10.1111/cas.70439

BibTeX
@article{Takagi2026,
  author = {Takagi, Kenji and Suzuki, Junpei and Matsuoka, Yuko and Kuwahara, Makoto and Oshikiri, Taro and Yamashita, Masakatsu},
  title = {Ezh2 Inhibits the Differentiation of Short‐Lived Effector CD8 + T Cells and Promotes T Cell‐Dependent Antitumor Immunity},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70439}
}
Kostenlos starten →